{
    "organizations": [],
    "uuid": "18e45e7a23e67c54405684f1c3b4974315a40882",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-agile-therapeutics-provides-regula/brief-agile-therapeutics-provides-regulatory-update-on-twirla-for-the-prevention-of-pregnancy-idUSASC0A2WX",
    "ord_in_thread": 0,
    "title": "BRIEF-Agile Therapeutics Provides Regulatory Update On Twirla® (Ag200-15) For The Prevention Of Pregnancy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 18 (Reuters) - Agile Therapeutics Inc:\n* AGILE THERAPEUTICS, INC. PROVIDES REGULATORY UPDATE ON TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY\n* AGILE THERAPEUTICS - ANNOUNCED CONTENT OF OFFICIAL MINUTES FROM TYPE A MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION HELD ON APRIL 16\n* AGILE THERAPEUTICS INC - IN CRL, FDA INFORMED COMPANY THAT TWIRLA NDA COULD NOT BE APPROVED\n* AGILE THERAPEUTICS - IN OFFICIAL MINUTES, FDA INFORMED CO IT CONTINUES TO HAVE SIGNIFICANT CONCERNS REGARDING ADHESION OF TWIRLA\n* AGILE THERAPEUTICS INC - FDA ALSO INFORMED CO IT WOULD NEED TO DEMONSTRATE BIOEQUIVALENCE TO DATA AND INFORMATION FOR ORIGINAL FORMULATION\n* AGILE - FDA SAID CO NEEDS TO ADDRESS TWIRLA ADHESION PROPERTIES BY REFORMULATING TRANSDERMAL SYSTEM, CONDUCT FORMAL ADHESION STUDY WITH NEW FORMULATION\n* AGILE THERAPEUTICS - FDA SAID AFTER CO SATISFIES QUESTIONS ON ADHESION, ADEQUATELY BRIDGES TO FINDINGS IN SECURE PHASE 3 TRIAL, IT ANTICIPATES DISCUSSING SAFETY & EFFICACY OF TWIRLA\n* AGILE THERAPEUTICS INC - TO EXTENT THAT CO REFORMULATES TWIRLA, IT MAY CREATE NEED FOR ADDITIONAL MANUFACTURING WORK AND REVIEW BY FDA\n* AGILE THERAPEUTICS INC - WHILE CO WILL CONTINUE TO EVALUATE ALL OPTIONS ON NEXT STEPS, EXPECT CO WILL PURSUE FORMAL DISPUTE RESOLUTION. Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-18T19:36:00.000+03:00",
    "crawled": "2018-05-19T15:27:47.021+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "agile",
        "therapeutic",
        "inc",
        "agile",
        "therapeutic",
        "provides",
        "regulatory",
        "update",
        "prevention",
        "pregnancy",
        "agile",
        "therapeutic",
        "announced",
        "content",
        "official",
        "minute",
        "type",
        "meeting",
        "food",
        "drug",
        "administration",
        "held",
        "april",
        "agile",
        "therapeutic",
        "inc",
        "crl",
        "fda",
        "informed",
        "company",
        "twirla",
        "nda",
        "could",
        "approved",
        "agile",
        "therapeutic",
        "official",
        "minute",
        "fda",
        "informed",
        "co",
        "continues",
        "significant",
        "concern",
        "regarding",
        "adhesion",
        "twirla",
        "agile",
        "therapeutic",
        "inc",
        "fda",
        "also",
        "informed",
        "co",
        "would",
        "need",
        "demonstrate",
        "bioequivalence",
        "data",
        "information",
        "original",
        "formulation",
        "agile",
        "fda",
        "said",
        "co",
        "need",
        "address",
        "twirla",
        "adhesion",
        "property",
        "reformulating",
        "transdermal",
        "system",
        "conduct",
        "formal",
        "adhesion",
        "study",
        "new",
        "formulation",
        "agile",
        "therapeutic",
        "fda",
        "said",
        "co",
        "satisfies",
        "question",
        "adhesion",
        "adequately",
        "bridge",
        "finding",
        "secure",
        "phase",
        "trial",
        "anticipates",
        "discussing",
        "safety",
        "efficacy",
        "twirla",
        "agile",
        "therapeutic",
        "inc",
        "extent",
        "co",
        "reformulates",
        "twirla",
        "may",
        "create",
        "need",
        "additional",
        "manufacturing",
        "work",
        "review",
        "fda",
        "agile",
        "therapeutic",
        "inc",
        "co",
        "continue",
        "evaluate",
        "option",
        "next",
        "step",
        "expect",
        "co",
        "pursue",
        "formal",
        "dispute",
        "resolution",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}